For ALK Rearrangement, Immunohistochemistry is Reliable Screening Tool

In several countries in US, Europe and Asia, favorable results have led to crizotinib gaining approval for the treatment of advanced stage ALK-positive non-small cell lung cancer (NSCLC).

Now, the identification of an effective therapy for ALK-positive NSCLC places great emphasis on rapid, accurate, and cost-effective way to find patients with this subtype of lung cancer. A recent study published in the January 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes immunohistochemistry (IHC) is a reliable screening tool for identification of ALK rearrangement.

Lung Cancer - Types, Causes, Symptoms, Diagnosis, Treatment and Prevention
Lung cancer is a malignant tumor in the lung tissues. Smoking is the main cause of lung cancer with symptoms like recurrent respiratory diseases.

Fluorescence in situ hybridization (FISH) is the current standard method to detect ALK rearrangement. However, FISH is not readily available as a routine method of pathology practice in most laboratories because it is time consuming and requires advanced technical and professional expertise. In contrast, IHC is relatively inexpensive, faster, and is perfectly adapted for routine practice by academics and most commu¬nity hospitals.

Researchers screened 377 stage I or II NSCLC cases, diagnosed between 1978 and 2002. Tissue microarray results were available on 377 cases by IHC and 273 cases by FISH. Eleven cases were positive or possibly positive by either IHC or FISH, and three cases were positive or possibly positive by both methods.

They found, "that all cases exhibiting ALK rearrangement demonstrated adenocarcinoma histology." Their results report a sensitivity of 100 percent and high specificity with the IHC with no false-negative results. While researchers acknowledge that further study involving a larger cohort is recommended, IHC is a valid screening test.

Lung Cancer Screening - FAQs
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can help in early detection of cancer and possible cure.

The lead author of this work is Dr. Chris M.J. Conklin. Co-authors include IASLC members Dr. Janessa Laskin, Dr. Kenneth Craddock, Cherry Have, Dr. Christian Couture and Dr. Diana Ionescu.

Source-Eurekalert

FDA Approves Abraxane for Treating Lung Cancer
The US FDA has approved Abraxane paclitaxel protein-bound particles to be used in combination with carboplatin for treating locally advanced or metastatic non-small cell lung cancer.

Dogs can Sniff Out Lung Cancer
In a recent study it was found that dogs are surprisingly proficient at sniffing out lung cancer, offering hope for earlier, life-saving diagnosis.